Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.
Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.
复制标题
DOI：
10.1016/j.exger.2009.10.003
复制
发表时间：
2010-01
影响因子：
3.9
通讯作者：
Smith, Mark A.
中科院分区：
文献类型：
--
作者：
Gustaw-Rothenberg, Katarzyna A.;Siedlak, Sandra L.;Bonda, David J.;Lerner, Alan;Tabaton, Massimo;Perry, George;Smith, Mark A.
随着有患阿尔茨海默病 (AD) 风险的老年人口不断增加，迫切需要一种灵敏、特异且最好是非侵入性的疾病进展诊断标准。主流观点认为，早期干预是最大限度地提高 AD 成功治疗方案机会的关键，因此，早期、准确的诊断方法至关重要。在这项研究中，我们将最近描述的抗体-抗原解离技术应用于作为基于人群的 AD 患病率分析的一部分而获得的样本。将分层抽样和随机选择策略相结合，以获得具有代表性的人群，用于筛选 55 岁以上的个体。在抗原解离前后测量淀粉样蛋白-β (Aβ)1-42 的血清抗体。两次测量之间的差异表示为解离增量 (Δ)。我们的分析表明，AD 患者的解离抗体水平始终与对照组显着不同，并且解离后的 Aβ 抗体水平（而非非解离水平）与 AD 患者的疾病持续时间和年龄呈负相关（p<0.05）。此外，Aβ抗体浓度从解离前到解离后的变化（即解离Δ）直接反映了AD在诊断后时间和患者年龄方面的进展，解离Δ越低表明AD处于更晚期阶段。最终，这些数据表明，解离的 Aβ 抗体水平在神经退行性过程开始时具有显着的诊断价值，并且此后可能是疾病进展的有用生物标志物。
With an ever growing population of aged individuals who are at risk of developing Alzheimer disease (AD), there is an urgent need for a sensitive, specific, and preferably non-invasive diagnostic standard of disease progression. Mainstream thinking suggests that early intervention is key to maximizing the opportunity for a successful treatment regimen in AD and, as such, an early and accurate means of diagnosis is essential. In this study, we applied a recently described antibody-antigen dissociation technique to samples obtained as part of a population-based analysis of the prevalence of AD. Stratified sampling and random selection strategies were combined to obtain a representative population for screening of individuals older than 55 years. Serum antibodies to amyloid-β (Aβ)1–42 were measured before and after antigen dissociation. The difference between the two measurements was indicated as the dissociation delta (Δ). Our analyses showed that the levels of dissociated antibody in AD patients were always significantly different from controls and that levels of Aβ antibody after dissociation, but not non-dissociated levels, correlated negatively (p<0.05) with both duration of the disease and age in the AD patients. Moreover, the change in concentration of Aβ antibody from pre- to post-dissociation (i.e., the dissociation Δ) directly reflected the progression of AD in terms of both time since diagnosis and age of the patients, with a lower dissociation Δ indicating a more advanced stage of AD. Ultimately, these data suggest that dissociated Aβ antibody levels are of significant diagnostic value at the onset of the neurodegenerative process and, thereafter, may be a useful biomarker for disease progression.
登录
查看更多内容
影响因子：
2.4
作者：
Li, QY;Cao, CH;Morgan, D
通讯作者：
Morgan, D
影响因子：
4
作者：
Quesada, JJ;Ferrucci, L;Bavazzano, A
通讯作者：
Bavazzano, A
影响因子：
4.8
作者：
Ida, N;Hartmann, T;Beyreuther, K
通讯作者：
Beyreuther, K
影响因子：
9.9
作者：
MCKHANN, G;DRACHMAN, D;STADLAN, EM
通讯作者：
STADLAN, EM
DOI：
10.1093/jnen/63.10.1028
发表时间：
2004-10-01
影响因子：
3.2
作者：
McKeel, DW;Price, JL;Morris, JC
通讯作者：
Morris, JC